Concepedia
Statistics
Publications
33
Citations
2.7K
H-Index
24
Active since
1989
Affiliations
Roche Pharma AG (Germany)(Current)
Heidelberg University
Roche (Switzerland)
Pharmalog (Germany)
Oslo University Hospital
Max Hasmann is an author at Roche Pharma AG (Germany) specializing in pharmacology, oncology, and molecular oncology.
Publications per year
1989–2022
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Max Hasmann, Isabel Schemainda · PubMed · 2003 · 635 citations
Life Sciences, Biochemistry, Pharmacology +17
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer, Thomas Friess, Helmut Burtscher et al. · Cancer Research · 2009 · 626 citations · Full text
Medicine, Oncology, Pharmacology +17
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement‐dependent anti‐tumor activity of trastuzumab and pertuzumab
Srinivas Mamidi, Marc Cinci, Max Hasmann et al. · Molecular Oncology · 2013 · 110 citations · Full text
Combination Treatment with Erlotinib and Pertuzumab against Human Tumor Xenografts Is Superior to Monotherapy
Thomas Friess, Werner Scheuer, Max Hasmann · Clinical Cancer Research · 2005 · 95 citations
Medicine, Oncology, Pharmacology +16
Metabolic Signatures Associated with a NAD Synthesis Inhibitor–Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy
Manickam Muruganandham, Alan Alfieri, Cornelia Matei et al. · Clinical Cancer Research · 2005 · 90 citations
Life Sciences, Oncology, Pharmacology +17
1–5 of 33